Search Results

Press Releases

Prokarium Expands IP Portfolio With Two New U.S. Patents Strengthening Its Position in Bladder Cancer

November 4, 2024

·

2 min read

Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial

Prokarium today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder cancer (NMIBC) patients (NCT06181266).

February 7, 2024

·

2 min read

Policy

Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program

Prokarium announces that the U.S. Food and Drug Administration has granted the company’s Investigational New Drug application for their immunotherapy ZH9.

November 2, 2023

·

3 min read

Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform

Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised $30 million in new funding.

February 9, 2023

·

4 min read

Business

Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop a bactofection platform to deliver RNA-based therapeutics.

January 9, 2023

·

5 min read

Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies

Prokarium Ltd, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office.

October 5, 2022

·

2 min read

Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline

Prokarium has entered into an agreement, through Imperial Projects, to work with independent researchers from Imperial College London to develop Prokarium’s next-generation therapeutic candidates, engineered to deliver payloads within the tumor microenvironment.

January 26, 2022

·

2 min read

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

Prokarium announced it exercised its option with Lausanne University Hospital for an exclusive, worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer.

March 2, 2022

·

3 min read

Business

Prokarium Appoints Industry Veteran Thomas Eldered as Chairman of the Board

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the appointment of Thomas Eldered as Chairman of the Board.

October 5, 2021

·

2 min read

Business

Prokarium Appoints Kristen Albright as Chief Executive Officer

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the appointment of Kristen Albright, PharmD, as Chief Executive Officer.

July 27, 2021

·

2 min read